Search all medical codes

Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as

CPT4 code

Name of the Procedure:

Quantitative Assessment of Urine Metabolites (Ascorbic Acid, Succinic Acid, Carnitine) via LC-MS/MS

Summary

This procedure measures levels of three specific metabolites (ascorbic acid, succinic acid, and carnitine) in urine samples. It uses a technology called liquid chromatography with tandem mass spectrometry (LC-MS/MS) to provide precise quantification. The results help in monitoring and managing colorectal oncology patients.

Purpose

The purpose of this procedure is to detect and quantify specific urine metabolites that could indicate changes related to colorectal cancer. It aims to monitor disease progression, treatment efficacy, and overall metabolic status of patients.

Indications

  • Patients diagnosed with colorectal cancer.
  • Patients undergoing treatment for colorectal cancer.
  • Monitoring recurrence in previously treated colorectal cancer patients.
  • Assessment of metabolic alterations associated with colorectal cancer.

Preparation

  • Patients may need to provide a urine sample, typically in the morning.
  • Fasting might be required before the urine collection.
  • Patients should inform their healthcare provider about any medications or supplements they are taking, as these could affect metabolite levels.

Procedure Description

  1. A urine sample is collected from the patient.
  2. The sample is prepared and subjected to liquid chromatography to separate the substances.
  3. Tandem mass spectrometry (LC-MS/MS) is used to detect and quantify ascorbic acid, succinic acid, and carnitine using multiple reaction monitoring acquisition.
  4. An algorithm interprets the data and reports the results.

Duration

The entire sample preparation and analysis process typically take a few hours, but this may vary depending on the lab's workflow and capacity.

Setting

This procedure is performed in a specialized laboratory equipped with LC-MS/MS technology.

Personnel

  • Medical laboratory scientists/technologists specialized in analytical chemistry.
  • Professional staff for sample collection and preparation.

Risks and Complications

  • As a non-invasive test (urine sample), it carries minimal risks.
  • Potential for inaccurate results due to improper sample collection or handling.

Benefits

  • Provides precise and accurate quantification of key metabolites.
  • Non-invasive and relatively quick.
  • Helps in effective monitoring and management of colorectal cancer.

Recovery

  • No recovery time is needed, as it is a simple urine test.
  • Patients can resume their normal activities immediately after sample collection.

Alternatives

  • Blood tests for metabolite analysis.
  • Imaging techniques for cancer monitoring.
  • Biopsy and histopathological analysis to directly evaluate cancer tissue.

Patient Experience

  • Minimal discomfort as it involves only urine collection.
  • Clear instructions are provided to ensure proper sample collection.
  • Patients will not experience pain or the need for sedation during this diagnostic test.

Medical Policies and Guidelines for Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as

Related policies from health plans

Similar Codes